| Patient | Pablo Neruda |
|---|---|
| Date of birth | 1959-07-12 |
| Identifiers | MRN HR-ML051-SYN; SSN (made up) 000-51-2976 |
| Document date | 2026-06-15 |
| Author | Étienne Okonkwo-Lund, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Man of 66 with four months of urinary symptoms and six weeks of right hip and low back pain, a hard nodular prostate, PSA 46.8 ng/mL and a raised alkaline phosphatase: suspected metastatic prostate cancer. Please confirm the diagnosis and extent and advise on treatment, including bone health and genetic testing. [S]
Urgency: Urgent, within two weeks. [S]
Questions for the consultant:
Mr. Neruda is seen at the request of Dr. Fairweather-Diaz, with a professional Spanish interpreter, for suspected metastatic prostate cancer. He has had four months of urinary frequency, a weak stream and nocturia, and six weeks of right hip and low back pain, now 5 of 10 on acetaminophen. He has no leg weakness, numbness, or change in bladder or bowel control, and no weight loss. He has hypertension treated with amlodipine and no other illness. He never smoked. Beyond his mother's death shortly after his birth, he does not know his family's medical history. He is fully active apart from the hip pain (ECOG 1), writes every morning and carries a full schedule of official duties. He asked for a plain account of the results and of every option. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
9 later historical claims are omitted because they describe events after the index age. See the teaching note.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-04-06 to 2026-07-13 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain | Two tablets up to three times daily as needed | Oral route | 2026-06-01 to 2026-09-14 | completed | S |
| Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food | One tablet once daily | Oral route | 2026-06-15 | active | S |
| Cholecalciferol (vitamin D3) 2000 units (0.05 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-15 | active | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed | resolved | confirmed | R97.20 | S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer. |
| Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1971 | active | confirmed | C61 | S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read. |
| Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites. |
| Pelvic lymph node metastases: right external iliac and right obturator nodes | active | confirmed | C77.5 | S — Synthetic nodal disease. |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognition | active | confirmed | Z79.899 | S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| Essential hypertension for five years, on amlodipine | active | confirmed | I10 | S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure. |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding at intake, addressed at the second visit. |
| Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis) | active | confirmed | M85.89 | S — Synthetic bone-health finding on the DXA before androgen deprivation. |
| Prediabetes (hemoglobin A1c 5.9%) | active | confirmed | R73.03 | S — Synthetic metabolic finding at intake, relevant to androgen deprivation. |
Vital signs recorded on 2026-06-15; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; walks without help, favoring the right hip slightly; ECOG 1 |
| Musculoskeletal | Tender over the right iliac crest; no midline spinal tenderness |
| Neurological | Strength 5 of 5 in both legs; sensation and reflexes normal |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-15 | DXA Femur [T-score] Bone density | -2.1 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 2026-06-15 | DXA Lumbar spine [T-score] Bone density | -1.4 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 2026-06-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-06-15 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | {score} | S |
Data reviewed: Multiparametric MRI of the prostate (52 mL gland; 24 mm PI-RADS 5 right peripheral zone lesion with extraprostatic extension; 13 mm right external iliac node); MRI-targeted biopsy (Gleason 4+4, Grade Group 4, in 9 of 14 cores, all on the right, with perineural invasion); CT of the chest, abdomen and pelvis (right external iliac 13 mm and obturator 11 mm nodes; sclerotic lesions in the right iliac wing and L5 without canal narrowing; no visceral disease); bone scan (two lesions only, right ilium and L5); gallium-68 PSMA PET/CT (concordant, no further disease); the first-visit laboratory tests; and this morning's DXA (femoral neck T-score -2.1, L1 to L4 -1.4). [S]